Immune-checkpoint blockade (ICB) targeting the PD-1/PD-L1 pathway mediates durable remissions in a subset of cancer patients, with these effects generally attributed to the reversal of CD8+ T cell exhaustion in tumor microenvironment (TME). This evidence concerns the gene CD274 and neoplasm.